Protia Inc. (KOSDAQ:303360)

Market Cap	75.33B
Revenue (ttm)	13.52B
Net Income (ttm)	3.80B
Shares Out	12.88M
EPS (ttm)	294.87
PE Ratio	19.84
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131,621
Average Volume	135,422
Open	5,710.00
Previous Close	5,710.00
Day's Range	5,600.00 - 6,020.00
52-Week Range	2,430.00 - 6,300.00
Beta	0.13
RSI	61.32
Earnings Date	n/a

About Protia

Protia Inc. designs, develops, and sells diagnostic kits in South Korea. The company offers PROTIA Allergy-Q, an assay kit for quantitative determination of specific IgE antibodies against individual allergens in human serum using immunoblotting technique; ImmuneCheck IgG, a whole blood test kit for total IgG concentration measurement; and TriCheck-C, an in vitro diagnostic kit for the qualitative test of human chorionic gonadotropin in human urine samples for the pregnancy diagnosis. It also provides protia food iga, a chronic food intolerance...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 303360

Financial Performance

In 2024, Protia's revenue was 10.51 billion, an increase of 27.79% compared to the previous year's 8.23 billion. Earnings were 2.44 billion, an increase of 427.52%.